Biotech Values

[DewDiligence]

Dew, do you have any idea what the terms are for ABT and Boston Scientific to compensate NVS for the m-tor inhibitor [everolimus] used to coat the stent, Xience [and Promus]?

To my knowledge, this has not been publicly disclosed.

Is there anything that obligates NVS not to provide this drug to competing stents?

Not that I know of; however, the question is probably moot. When you add JNJ’s Nevo (which uses sirolimus revervoirs—see #msg-37962147) to the array of currently marketed drug-eluting stents (#msg-39762286), there is not a lot of room left for new entrants. Regards, Dew